Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Earth's newfound 'episodic-squishy lid' may guide our search for habitable worlds - 2Reviving Your Home with Nutritious Indoor Plants
- 3Trump says Venezuela will start 'turning over' oil to the U.S. Is that the reason he toppled Maduro — or is it something else?
- 4'No Kings' protests recap: More than 8 million turned out across all 50 states, organizers say
- 5Sean 'Diddy' Combs faces new sexual assault allegations, currently under investigation by Los Angeles Sheriff's Department
- IDF Home Front Command extends siren warning times for Hezbollah rockets in North
- What you need to know about flu treatments as cases spike across the US
- Anti-war protests held across Israel under wartime gathering limits
- The Best Computer games for Multiplayer Fun
- IDF destroys regime's missile, sea mine production site in Yazd amid nationwide airstrikes
- Israel strikes Iranian nuclear development facilities, Tehran vows retaliation
- Top 15 Supportable Design Brands Coming out on top
- Israel Police arrest twenty-one as anti-war protests grow despite broad support for Iran war
- Sea Ice Hits New Low in Hottest Year on Record for the Arctic
